Supplementary Figure S7 from Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial

• DOI: 10.1158/1078-0432.28606422
• Publication Date: 2025-03-17T07:22:05Z
• Authors: Marcelo V. Negrao; Alvaro G. Paula; David Molkentine; Laura Hover; Monique Nilsson; Natalie Vokes; Lars Engstrom; Andrew Calinisan; David M. Briere; Laura Waters; Jill Hallin; Lixia Diao; Mehmet Altan; George R. Blumens...; Ferdinandos Skoul...; Jing Wang; Scott E. Kopetz; David S. Hong; Don L. Gibbons; Peter Olson; James G. Christensen; John V. Heymach

<p>Supplementary Figure S7. Clinical outcomes to adagrasib monotherapy according to NRF2 score and <i>STK11</i> co-mutation status in <i>KEAP1</i>^<i>WT</i>/<i>KRAS</i>^<i>G12C</i>-mutant NSCLC patients.</p>